Thura, Min
Al-Aidaroos, Abdul Qader http://orcid.org/0000-0003-0330-6606
Gupta, Abhishek
Chee, Cheng Ean
Lee, Soo Chin
Hui, Kam Man
Li, Jie
Guan, Yeoh Khay
Yong, Wei Peng
So, Jimmy
Chng, Wee Joo
Ng, Chin Hin
Zhou, Jianbiao http://orcid.org/0000-0002-5679-671X
Wang, Ling Zhi
Yuen, John Shyi Peng
Ho, Henry Sun Sien
Yi, Sim Mei http://orcid.org/0000-0001-6546-4699
Chiong, Edmund
Choo, Su Pin
Ngeow, Joanne
Ng, Matthew Chau Hsien
Chua, Clarinda
Yeo, Eugene Shen Ann
Tan, Iain Bee Huat
Sng, Joel Xuan En
Tan, Nicholas Yan Zhi
Thiery, Jean Paul
Goh, Boon Cher
Zeng, Qi
Funding for this research was provided by:
A*STAR | Institute of Molecular and Cell Biology
Article History
Received: 11 April 2018
Accepted: 23 April 2019
First Online: 6 June 2019
Change Date: 2 November 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-021-26548-6
Competing interests
: Q.Z. is the founder of Intra-Immu SG Pte Ltd., an Agency of Science, Technology and Research (A*STAR) spin-off company granted licensing rights for the PRL3-zumab IP portfolio. The other authors declare no competing interests.